ES2463715T3 - Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano - Google Patents

Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano Download PDF

Info

Publication number
ES2463715T3
ES2463715T3 ES08735211.8T ES08735211T ES2463715T3 ES 2463715 T3 ES2463715 T3 ES 2463715T3 ES 08735211 T ES08735211 T ES 08735211T ES 2463715 T3 ES2463715 T3 ES 2463715T3
Authority
ES
Spain
Prior art keywords
galantamine
brain
gal
treatment
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08735211.8T
Other languages
English (en)
Spanish (es)
Inventor
Alfred Maelicke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurodyn Life Sciences Inc
Galantos Pharma GmbH
Original Assignee
Neurodyn Life Sciences Inc
Galantos Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2463715(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurodyn Life Sciences Inc, Galantos Pharma GmbH filed Critical Neurodyn Life Sciences Inc
Application granted granted Critical
Publication of ES2463715T3 publication Critical patent/ES2463715T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES08735211.8T 2008-04-14 2008-04-14 Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano Active ES2463715T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/002929 WO2009127218A1 (en) 2008-04-14 2008-04-14 Derivatives of galantamine as pro-drugs for the treatment of human brain diseases

Publications (1)

Publication Number Publication Date
ES2463715T3 true ES2463715T3 (es) 2014-05-29

Family

ID=40019199

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08735211.8T Active ES2463715T3 (es) 2008-04-14 2008-04-14 Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano

Country Status (8)

Country Link
EP (1) EP2137192B8 (enExample)
JP (1) JP5504253B2 (enExample)
CN (1) CN102007129B (enExample)
CA (1) CA2721007C (enExample)
DK (1) DK2137192T3 (enExample)
ES (1) ES2463715T3 (enExample)
PL (1) PL2137192T3 (enExample)
WO (1) WO2009127218A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700473T3 (es) * 2012-07-27 2019-02-18 Neurodyn Life Sciences Inc Biodisponibilidad cerebral mejorada de galantamina mediante formulaciones seleccionadas y administración transmucosa de profármacos lipofílicos
ES2880399T3 (es) 2012-07-27 2021-11-24 Neurodyn Life Sciences Inc Biodisponibilidad cerebral mejorada de galantamina mediante formulaciones seleccionadas y administración transmucosa de profármacos lipofílicos
WO2015148480A1 (en) 2014-03-25 2015-10-01 Emicipi Llc Treatment of rett syndrome
US10561665B2 (en) * 2014-03-25 2020-02-18 Synaptec Development Llc Treatment of autism
AU2015258814B2 (en) * 2014-05-16 2018-04-05 Synaptec Development Llc Clearance of amyloid ss
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate
EP4186509A1 (en) 2021-11-26 2023-05-31 Alpha Cognition Inc. Alpha-1062 for treating traumatic brain injury
US12208167B1 (en) 2024-02-06 2025-01-28 Alpha Cognition Inc. Coated tablets for pH-dependent release of benzgalantamine
US12551491B1 (en) * 2025-07-23 2026-02-17 Alpha Cognition Inc. Dosage regimens for benzgalantamine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3856594D1 (de) 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU1282099A (en) * 1997-10-29 1999-05-17 Bonnie M. Davis Method for treatment of disorders of attention
AU1430099A (en) 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
AU780012B2 (en) 1999-12-10 2005-02-24 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
CN1380883A (zh) 2000-03-31 2002-11-20 萨诺化学药物股份公司 雪花胺的新衍生物和类似物
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US7307162B2 (en) 2003-09-26 2007-12-11 Scinopharm Taiwan, Ltd. Resolution of a narwedine amide derivative
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

Also Published As

Publication number Publication date
DK2137192T3 (da) 2014-05-26
JP2011516588A (ja) 2011-05-26
CN102007129A (zh) 2011-04-06
CA2721007C (en) 2014-04-29
CN102007129B (zh) 2014-05-07
WO2009127218A1 (en) 2009-10-22
EP2137192B1 (en) 2014-02-19
EP2137192A1 (en) 2009-12-30
JP5504253B2 (ja) 2014-05-28
PL2137192T3 (pl) 2014-07-31
EP2137192B8 (en) 2014-06-11
CA2721007A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
US10265325B2 (en) Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
ES2945834T3 (es) Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30)
CA2721007C (en) Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
ES3060138T3 (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
ES2463452T3 (es) Pirimidin-2,4-diaminas y sus usos
ES2348334T3 (es) Potenciadores colinérgicos con permeabilidad de la barrera hematoencefálica mejorada para el tratamiento de enfermedades acompañadas de deterioro cognitivo.
ES2872378T3 (es) Agonistas de receptores muscarínicos
ES2622703T3 (es) Nuevos compuestos de estructuras miméticas de código inverso y uso de los mismos
ES2567605T3 (es) Nuevo compuesto de imidazo-oxazina o sal del mismo
ES2268633T3 (es) Pirrolopirimidinas espiro sustituidas.
US8816122B2 (en) Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use
EP3392252B1 (en) Pyrimido- pyridazinone compounds and use thereof
Basiri et al. Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives
US10100090B2 (en) Substituted urea depsipeptide analogs as activators of the CLPP endopeptidase
Tan et al. Synthesis of mimics of pramanicin from pyroglutamic acid and their antibacterial activity
Diethelm et al. Access to the aeruginosin serine protease inhibitors through the nucleophilic opening of an oxabicyclo [2.2. 1] heptane: total synthesis of microcin SF608
ES2284519T3 (es) Derivados de piperidina 4-sustituida.
ES2206449T3 (es) Inhibidores de colinesterasas, composiciones farmaceuticas y sus usos.
CN111253412A (zh) α-倒捻子素衍生物及其应用
Price et al. Structural insights into the design of reversible fluorescent probes for metallo-β-lactamases NDM-1, VIM-2, and IMP-1
CN114929223A (zh) 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物
WO2019152527A1 (en) Pipecolic esters for inhibition of the proteasome
HK40107186A (en) Pyrimido- pyridazinone compounds and use thereof
HK1262920B (en) Pyrimido- pyridazinone compounds and use thereof
Wachter Chemical synthesis of small molecule libraries around the p-benzoquinone scaffold